Lead storyLead story · #earnings
Moderna returns to profit—but its cash rise comes with new debt
Moderna rose 5.27% after stronger vaccine sales and lower research costs lifted Q3 profit. Convertible financing and November 12 Analyst Day keep the risks in focus.







